"uuid:ID","description","label","name","id","rationale"
"c8ac5eb5-bf48-4040-b269-3ff25ae871c7","The main design for the study","","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
